BioCentury This Week

Ep. 370 - Calmer waters for FDA; Servier, Lilly deals

Ep. 369 - ASCO advances, China innovation & U.S. science under threat

Ep. 368 - ASCO Preview, China Policy, ADC Linkers

Ep. 367 - FDA, obesity targets and the rise of DACs

Ep. 366 - Europe's need for speed: Bio€quity takeaways

Ep. 365 - Thin ice for Makary, redosing AAVs

Ep. 364 - UCB’s Candid buy, Grand Rounds and leukodystrophies

Biopharma industry developments center on the $2 billion acquisition of Candid Therapeutics by UCB, signaling a strategic shift toward T cell engagers for autoimmune applications. This move underscores the necessity of clinical proof-of-concept in a crowded landscape. Leukodystrophy research is simultaneously evolving,...

Ep. 363 - New targets at AACR, biopharma deals, Kurma fund

Ep. 362 - AACR: Data and de-risking

Ep. 361 - Kelonia, Kailera, pyschedelics and T cell engagers

Ep. 360 - FDA’s FIH plans. Plus: billion-dollar deals, funds

The FDA is proposing a new regulatory pathway to accelerate First-in-Human clinical trials by allowing non-animal, new approach methods to substitute for traditional toxicology requirements. While this initiative aims to reduce development time and costs, it faces significant hurdles, including the need for congression...

Ep. 359 - 2Q markets preview, tariffs and biotech takeouts

The podcast explores the biotech industry's resilience amid global uncertainties, focusing on M&A activity and potential impacts of the Middle East conflict. It highlights the sector's strong performance in the first quarter, driven by M&A deals and positive clinical readouts, but notes concerns about prolonged conflic...

Ep. 358 - Europe's biotech challenge

The BioCentury This Week podcast explores how European biotech can compete in an era prioritizing speed in clinical data generation, particularly given the rise of China's biotech industry. The discussion highlights the need for Europe to streamline clinical trials and regulatory processes to remain competitive, addres...

Ep. 357 - Deal-O-rama, Gilead and Tallon's U.K. vision

Ep. 356 - Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN

The BioCentury This Week podcast covers recent developments in the biotech industry, including Arrowhead's progress towards becoming a large-cap biotech and Synnovation's $2 billion deal with Novartis. The discussion highlights Arrowhead's journey, from its nanotech origins to its current focus on RNAi therapeutics, em...

Ep. 355 - Capital market mood, Xenon data, Friedreich ataxia pipeline

Ep. 354 - East-West Summit Takeaways

Ep. 353 - Prasad Departure and Future of Fibrosis Therapies

Ep. 352 - A Multipolar Biopharma World; Rare Disease Spotlight

Ep. 351 - Gilead's Arcellx Buy. Plus: ctDNA as Surrogate Endpoint